ISIS-TTRRx: Phase I data

A double-blind, Phase I trial in about 50 healthy volunteers showed that 200 and 400 mg subcutaneous ISIS-TTRRx significantly reduced mean serum TTR levels by 44% and 81%, respectively, vs. an increas...